Table 1. Efficacy of PI3K inhibitors in... | American Society of Hematology

Table 1.

Efficacy of PI3K inhibitors in patients with r/r DLBCL

Drug	Targets	n	Treatment	ORR, %	Reference
Buparlisib	Pan-class I PI3K	26	Monotherapy	11.5	93
Copanlisib	Pan-PI3K, with preferential inhibition of PI3Kα and PI3Kδ	15	Monotherapy	6.7	110
Copanlisib	Pan-PI3K, with preferential inhibition of PI3Kα and PI3Kδ	67	Monotherapy	19.4 (31.6 in ABC, 13.3 in GCB)	90
CUDC-907	PI3Kα, β, and δ, histone deacetylase	37	Monotherapy or combined with rituximab	37	97
Umbralisib	PI3Kδ	26	Combined with ublituximab	23	102
Parsaclisib	PI3Kδ	60	Monotherapy	25.5	94

Drug	Targets	n	Treatment	ORR, %	Reference
Buparlisib	Pan-class I PI3K	26	Monotherapy	11.5	93
Copanlisib	Pan-PI3K, with preferential inhibition of PI3Kα and PI3Kδ	15	Monotherapy	6.7	110
Copanlisib	Pan-PI3K, with preferential inhibition of PI3Kα and PI3Kδ	67	Monotherapy	19.4 (31.6 in ABC, 13.3 in GCB)	90
CUDC-907	PI3Kα, β, and δ, histone deacetylase	37	Monotherapy or combined with rituximab	37	97
Umbralisib	PI3Kδ	26	Combined with ublituximab	23	102
Parsaclisib	PI3Kδ	60	Monotherapy	25.5	94